Genocure Establishes Strategic Partnership

with Communication AI Corporation ‘ANYCHAT’

for Convergence of DNA(PDRN) Data and AI Technology

- Expected to enter the regenerative medical market based on AI technology

through PDRN DNA data research using AI technology -

Nov. 4, 2024

(L) CEO of ANYCHAT, Lee Seung-jin (R) CEO of Genocure, Oh Bo-gyeong 

A regenerative biomaterial specialized company, Genocure Co., Ltd. (CEO Oh Bo-gyeong, www.genocure.co.kr) established a strategic partnership for convergence of DNA(PDRN) data and AI technology with ANYCHAT(CEO Lee Seoung-jin), which provides the communication AI service, ‘ANYCHAT’.

Genocure is a bio venture startup, that is now entering the global regenerative medical market through the supply of PDRN as a raw material for pharmaceuticals, medical devices, and cosmetics, and the development of PDRN-related finished products, based on the technology of extracting and producing PDRN of high purity and the research and development on the next-generation PDRN.

ANYCHAT is a ‘communication AI’ specialized company, providing a global service, ‘ANYCHAT’, which allows messenger conversations between different languages based on artificial intelligence technology. ANYCHAT stated that they established a strategic partnership with Genocure by highly evaluating the possibility of introducing a new regenerative medical service based on AI technology by fusing the AI technology accumulated with Genocure’s PDRN DNA data.

Oh Bo-gyeong, CEO of Genocure, said, “With this strategic partnership with ANYCHAT, we will offer a new business model that combines PDRN DNA data obtained through next-generation PDRN research and development with artificial intelligence technology.” She also added that Genocure will supply pharmaceutical-grade, high-purity PDRN through the bGMP certification and expend sales through ‘various regenerative medical businesses using PDRN’.